• View Press Releases

    View Press Releases

News & Media

Recent News

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma More

Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma More

Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia More

View All News

Quick Facts

Year founded 1998

Nasdaq SGEN

Number of Employees 1,000+

Global Headquarters Bothell, WA

European Headquarters Zug, Switzerland

icon-sw.png

Primary Product ADCETRIS

adcetris.png

Disease Focus Areas Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, urothelial cancer, breast cancer

heart.png

Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+

Resources

Social Media

 

Media Contacts

For Media Professionals Only

Brandi Robinson

Sr. VP, Corporate Communications

media@seagen.com